Nov. 2, 2009 (World Stock Wire) --
Las Vegas, NV - (WORLD STOCK WIRE) - November 2, 2009 -- DrStockPick.com tracks stocks daily and is pleased to offer its hot stock alerts. Investors can receive FREE Stock Alerts by visiting DrStockPick.com at the following link: http://www.drstockpick.com.
Today’s alerts include: Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN), Vertex Pharmaceuticals Inc. (Nasdaq: VRTX) and Human Genome Sciences, Inc. (Nasdaq: HGSI).
About Amylin Pharmaceuticals, Inc.
Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. The U.S. Food and Drug Administration (FDA) has approved an expanded indication for Amylin’s BYETTA® (exenatide) injection. BYETTA is now approved for use as a stand-alone medication (monotherapy) along with diet and exercise to improve glycemic control in adults with type 2 diabetes. Furthermore, Amylin Pharmaceuticals and Takeda Pharmaceutical Company Limited (OOTC:TKPHY) have entered into a worldwide exclusive license, development and commercialization agreement to co-develop and commercialize pharmaceutical products for the treatment of obesity and related indications. Vertex'
About Vertex Pharmaceuticals Inc.
Vertex Pharmaceuticals engages in the discovery, development, and commercialization of small molecule drugs for the treatment of serious diseases worldwide. Vertex reported that more than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response with a telaprevir-based regimen according to results of an intent-to-treat analysis. Telaprevir is a hepatitis C virus protease inhibitor being developed by Vertex Pharmaceuticals Incorporated in collaboration with Tibotec and Mitsubishi Tanabe Pharma.
About Human Genome Sciences, Inc.
Human Genome Sciences operates as a biopharmaceutical company in the United States. The companys clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. Human Genome and GlaxoSmithKline PLC reported Positive Results in Second of Two Phase 3 Trials of BENLYSTA in Systemic Lupus Erythematosus. Human Genome has responsibility for conducting the belimumab Phase 3 trials, with assistance from GlaxoSmithKline. The companies will share equally in Phase 3/4 development costs, sales and marketing expenses, and profits of any product commercialized under the current agreement.
ABOUT DRSTOCKPICK.COM
DrStockPick.com is a stock watch website that provides free daily alerts on stocks. DrStockPick.com's alerts are daily e-mail on stocks that are hot in the market. These include stocks with huge volume, penny stocks, stocks with technical indicators and much more.
